Pharmacy-Based HIV Prevention Services

APhA's Pharmacy-Based HIV Prevention Services Certificate Training Program sets pharmacists up for success when providing HIV prevention and sexual wellness services to their patients. This comprehensive training program reviews HIV as a disease state, pharmacology of currently available PrEP and PEP medications, CDC guideline recommendations for provision of PrEP and PEP, and the building blocks of communication methods for discussing sexual health. In addition to HIV prevention care, this training program will discuss epidemiology and pathophysiology, screening, and pharmacotherapy of sexually transmitted infections and the importance of providing harm reduction care in your pharmacy. An optional 4-hour micro-credential titled “Implementing HIV Prevention Services” rounds out this training that reviews workflow considerations, billing and coding, and patient referrals to care. A total of 16 hours of CPE are available in this program. The micro-credential is available for individual purchase and is accredited for both pharmacists and technicians.

Please Note: If you have already purchased APhA's Pharmacy-Based HIV Prevention Services Certificate Training Program from APhA or another partner, you should not purchase the micro-credential. The micro-credential is available to all learners who are enrolled in APhA's Pharmacy-Based HIV Prevention Certificate Training Program.

Pricing

Certificate Training Program Pricing:

Member Price: $299
Nonmember Price: $599

If your company or organization is interested in offering this program to your pharmacists or student pharmacists, please contact Chris McKerrow.

Micro-credential Pricing:

Member Price: $99
Nonmember Price: $149

If your company or organization is interested in offering this program to your pharmacists or student pharmacists, please contact Chris McKerrow.

Learning Objectives & Module Details

This course contains the following contents:

Pharmacy-Based HIV Prevention Services ACPE Information
Pharmacy-Based HIV Prevention Services Contributors List
Pharmacy-Based HIV Prevention Services Pre-Course Knowledge Check
Module 1: Terms, Definitions, and Background
Module 2: PrEP and PEP Uptake and Disparities in Use
Module 3: Pharmacology
Module 4: Summary of PrEP and PEP Guidelines
Module 5: Review of Sexually Transmitted Infections (STIs)
Module 6: Communicating About PrEP and PEP with Cultural Humility
Module 7: Bringing It All Together

Module 1: Terms, Definitions, and Background

A Review of HIV

At the completion of this activity, participants will be able to:

Discuss pathophysiology and immunology of HIV, including relevant signs and symptoms.
Recall the evolution of HIV care and the HIV care continuum.

HIV Prevention Strategies

At the completion of this activity, participants will be able to:

List the primary modes of HIV transmission.
Recall pharmacologic treatment options for HIV prevention.
Discuss barriers to HIV prevention efforts.

Defining PrEP and PEP

At the completion of this activity, participants will be able to:

Describe the role of antiretrovirals in HIV therapy.
List key differences between PrEP and PEP.
Recall important moments in the history of PrEP and PEP.

Module 2: PrEP and PEP Uptake and Disparities in Use

Caring for Diverse Populations

At the completion of this activity, participants will be able to:

List populations in the United States most impacted by HIV disease.
Describe current trends in uptake of PrEP and PEP against acquisition in the United States.
Discuss strategies to improve PrEP and PEP uptake among populations most impacted by HIV.

Syndemics and Ending the HIV Epidemic

At the completion of this activity, participants will be able to:

Define the term “syndemic”.
List reasons why considering HIV as part of a larger syndemic is necessary to end the HIV epidemic in the U.S.
Identify strategies that can be implemented in your workplace to address the syndemic of HIV.

HIV and Harm Reduction Strategies

At the completion of this activity, participants will be able to:

List harm reduction strategies.
Describe how harm reduction impacts HIV.

Module 3: Pharmacology

PrEP Pharmacology

At the completion of this activity, participants will be able to:

Explain the relative effectiveness of available PrEP medications.
Compare and contrast available oral PrEP medications.
Describe current cabotegravir utility including adherence, follow-up testing, and prescribing requirements.

PEP Pharmacology

At the completion of this activity, participants will be able to:

Explain the relative effectiveness of available PEP medications.
Compare and contrast available PEP medications.

Adverse Effects of PrEP and PEP

At the completion of this activity, participants will be able to:

Discuss start-up syndrome.
Identify common and significant adverse effects associated with PrEP and PEP.

Common PrEP and PEP Drug Interactions

At the completion of this activity, participants will be able to:

Identify drug interactions associated with PrEP and PEP.
Differentiate management of potential drug-drug interactions with the use of PrEP and PEP based on interaction type and severity.

Module 4: Summary of PrEP and PEP Guidelines

Guideline Recommendations: PrEP

At the completion of this activity, participants will be able to:

Describe current indications and contraindications for PrEP.
Identify when referral to a physician for PrEP therapy is appropriate.

Guideline Recommendations: PEP

At the completion of this activity, participants will be able to:

Describe current indications and contraindications for PEP.
Identify when referral to a physician for PEP therapy is appropriate.

Patients with Comorbidities

At the completion of this activity, participants will be able to:

Discuss approaches to PrEP and PEP therapies in patients with comorbid conditions.
Recognize relevant labs for specific patient populations on PrEP and PEP.

Legislative Update

At the completion of this activity, participants will be able to:

Explain legislation and steps states have taken to expand pharmacists’ scope in providing PrEP and PEP.
Identify education and training requirements for pharmacists to provide PrEP and/or PEP in their state.

Module 5: Review of Sexually Transmitted Infections (STIs)

Epidemiology and Pathophysiology of STIs

At the completion of this activity, participants will be able to:

Review pathophysiology and epidemiology of STIs including gonorrhea, chlamydia, and syphilis.
Describe symptoms and disease progression of gonorrhea, chlamydia, and syphilis.

Screening for STIs

At the completion of this activity, participants will be able to:

Describe guideline recommended screening procedures for STIs.
Discuss the pharmacist’s role in STI screening.

Pharmacotherapy of STIs

At the completion of this activity, participants will be able to:

Identify STI treatment regimens for gonorrhea, chlamydia, and syphilis.
Recognize when PrEP and PEP prescribing may be appropriate in the setting of STI treatment.

Module 6: Communicating About PrEP and PEP with Cultural Humility

Providing Culturally Competent Communication

At the completion of this activity, participants will be able to:

Describe how to communicate with impacted communities.
Review definitions and common/accepted terms.

Identifying Barriers to PrEP and PEP

At the completion of this activity, participants will be able to:

Describe how barriers such as social determinants of health and lack of provider education impact access to PrEP and PEP.
Discuss how barriers impact uptake of PrEP and PEP.

Removing Stigma

At the completion of this activity, participants will be able to:

Discuss approaches in de-stigmatizing the use of PrEP and PEP.

Obtaining a Patient’s History: Beyond PMH

At the completion of this activity, participants will be able to:

Describe principles of inclusivity as they relate to obtaining a sexual and drug history.
Discuss best practices in obtaining a sexual and drug history in all patients.
Outline key questions to ask and how to respond to questions while obtaining a patient's history.

Trauma-Informed Care: Prescribing PrEP and PEP

At the completion of this activity, participants will be able to:

Describe the impact of trauma on an individual’s engagement with HIV prevention services.
Review strategies and techniques for integration of trauma-informed care into clinical practice when prescribing and counseling on PrEP and PEP care.

Communicating a Positive Result

At the completion of this activity, participants will be able to:

Discuss potentially distressing nature of a new HIV diagnosis.
Review best practices for communicating a potentially distressing test result.
Outline CDC recommendations and important counseling points regarding HIV infection.
Describe impact of effective communication of positive HIV test results.

HIV Prevention Strategies

At the completion of this activity, participants will be able to:

Practice general principles of communicating with cultural humility as an effective strategy in HIV prevention.
Choose appropriate responses to a patient interaction discussing PrEP.

Module 7: Bringing It All Together

Bringing It All Together: A Case Study

At the completion of this activity, participants will be able to:

Assess appropriateness of PrEP or PEP therapy in a patient case.
Propose a care plan, including monitoring and laboratory parameters for patients initiated on PrEP or PEP.

Implementing HIV Prevention Services Micro-credential

Defining PrEP and PEP

Describe the role of antiretrovirals in HIV therapy.
List key differences between PrEP and PEP.
Recall important moments in the history of PrEP and PEP.

Pathways to PrEP and PEP at Your Pharmacy

Review models to provide PrEP and PEP services in a variety of work settings.

The Role of the Team

Explain the role of each staff member in the process of providing PrEP and PEP at specific practice sites.

Preparing the Site for PrEP and PEP

Discuss steps in preparing the site to provide PrEP and PEP services.
List potential space specifications for a successful patient encounter.
Outline the implementation of protocols such as how to set up laboratory and point-of-care testing.
Describe the application process for a Clinical Laboratory Improvement Amendments (CLIA) waiver license.
Identify supplementary harm reduction services the site can provide.
Describe the documentation requirements for patient care visits related to PrEP and PEP.

Referring Patients

Discuss situations where referral to other providers and organizations is needed.
List strategies on how to communicate information with other members of a patient’s care team.

Costs of PrEP and PEP

Review pharmacoeconomic data on pharmacist run PrEP and PEP clinics.
Identify low cost, and simple solutions for implementing a PEP or PrEP program.

Billing and Coding for the Patient Visit

Define common reimbursement language.
Identify billing codes for patient care visits and laboratory services.
Review pharmacists’ medical billing, collaborative practice, and direct billing models.
Discuss reimbursement of telehealth services.

Community Outreach Strategies

Discuss community outreach strategies to increase education on PrEP and PEP through non-traditional partnerships.

How to Obtain a Certificate of Completion

Complete 7 self-study modules, each of which consists of an interactive eLearning module or a podcast and a knowledge check. Micro-credential participants must complete 8 self-study modules, each of which consists of an interactive eLearning module or a podcast and a knowledge check.
Achieve a passing grade of 50% or higher on each knowledge check and a passing grade of 70% or higher on the final assessment.
Complete all course evaluations.
Participants will need to have a valid APhA (pharmacist.com) username and password, as well as a CPE Monitor account to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
The Certificate of Completion will be available online upon successful completion of all 7 module activities on the participant's My Training page. A separate Certificate of Completion will be available for micro-credential learners.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete a continuing pharmacy education assessment. Please note that you will not be permitted to submit an assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This is intended to maintain the integrity of the CPE activity and the assessment.

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. APhA's Pharmacy-Based HIV Prevention Services Certificate Training Program is approved for a total of 12.0 contact hours of continuing pharmacy education (CPE) credit (1.2 CEUs). The ACPE Universal Activity Number (UAN) for this activity is listed below.

ACPE UAN: 0202-0000-24-190-H02-P
Activity Type: Certificate Program
Target Audience: Pharmacists
Release Date: February 28, 2024
Expiration Date: February 28, 2027 - PLEASE NOTE: NO Home Study credit granted after this date.

APhA's Implementing HIV Prevention Services Micro-credential is approved for a total of 4.0 contact hours of continuing pharmacy education (CPE) credit (0.4 CEUs). The ACPE Universal Activity Number (UAN) for this activity is listed below.

ACPE UAN: 0202-0000-24-381-H02-P/T
Activity Type: Knowledge-based
Target Audience: Pharmacists and technicians
Release Date: December 23, 2024
Expiration Date: December 23, 2027 - PLEASE NOTE: NO Home Study credit granted after this date.

Technology Requirements and Tips

Computer and Internet access are required to complete this activity. If you experience technical difficulties, try a different web browser.

Please be aware that if the system detects no activity for an extended amount of time while the screen is open in the interactive activity, the Next button may freeze, and you will need to Restart that activity again.

The recommendation is that if you cannot complete the activity within one sitting and need to step away, close the activity so that your place is bookmarked.

If you continue to experience difficulties, please reach out to education@aphanet.org with the name of course, details of your experience, which web browser(s) used and if possible, screenshots.

Faculty

Advisory Board

Betty J. Dong, PharmD, FCCP, FASHP, FAPhA, AAHIVP

Professor of Clinical Pharmacy
University of California, San Francisco
San Francisco, CA

Disclosure: Presenter, International AIDS Society-US

Neelam ‘Nelly’ Gazarian, PharmD, MS, AAHIVP, LCDR USPHS

Senior Policy Analyst
Office of Infectious Disease and HIV/AIDS Policy
Washington, D.C.

Disclosure: Author has nothing to disclose

Maria Lopez, PharmD (Chair)

President
Mission Wellness
San Francisco, CA

Disclosure: Owner, Mission Wellness Pharmacy

Alex R. Mills, PharmD, BCACP, AAHIVP

Ambulatory Cardiology Clinical Pharmacist
Community Health Network
Indianapolis, IN

Disclosure: Author has nothing to disclose

Dan Scales, PharmD, MHA, AAHIVP

Director of Clinical Pharmacy
Vivent Health
Denver, CO

Disclosure: Author has nothing to disclose

Authors

Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES

Associate Professor
University of South Florida Taneja College of Pharmacy
Tampa, FL

Disclosure: Author has nothing to disclose

Alsean Bryant, PharmD, AAHIVP, HIV PCP

Senior Medical Science Liaison
Gilead Sciences
Jacksonville, FL

Disclosure: Employee, Gilead – author was previously employed at AIDS Healthcare Foundation at the time of content development.

Anthonia Chimezie, PharmD, BCACP, AAHIVP

Clinical Pharmacist
University of California, San Francisco
San Francisco, CA

Disclosure: Author has nothing to disclose

Jennifer Cocohoba, PharmD, MAS

Professor of Clinical Pharmacy
University of California, San Francisco
San Francisco, CA

Disclosures: Institution research grant, ViiV Healthcare; Contract (Industry Fellowship), Genentech, Inc.; Contract (Industry Fellowship), Janssen Pharmaceuticals

Della C. Cutchins, PharmD, MPH, BCPS, CAPT USPHS

Public Health Program Specialist/Informaticist
Alaska Native Tribal Health Consortium
Anchorage, AK

Disclosure: Author has nothing to disclose

Betty J. Dong, PharmD, FCCP, FASHP, FAPhA, AAHIVP

Professor of Clinical Pharmacy
University of California, San Francisco
San Francisco, CA

Disclosure: Presenter, International AIDS Society-USA

Cassandra Esperant, PharmD, AAHIVP

CEO & Founder
PrEPRx
Fort Lauderdale, FL

Disclosure: Author has nothing to disclose

Neelam ‘Nelly’ Gazarian, PharmD, MS, AAHIVP, LCDR USPHS

Senior Policy Analyst
Office of Infectious Disease and HIV/AIDS Policy
Washington, D.C.

Disclosure: Author has nothing to disclose

Andrew Gentles, PharmD, MPH, BCPS, FAPhA, CDR USPHS

Senior Regulatory Health Scientist
Centers for Disease Control and Prevention
Atlanta, GA

Disclosure: Author has nothing to disclose

Marie Johnston, PharmD, MPH, CDR USPHS

Health Scientist, Division of HIV Prevention
Centers for Disease Control and Prevention
Atlanta, GA

Disclosure: Author has nothing to disclose

Hailey Keeser, PharmD, AAHIVP, CDCES

Clinical Pharmacist
Vivent Health
Elm Grove, WI

Disclosure: Author has nothing to disclose

Deborah A. Long, PharmD, BCIDP, BCPS, AAHIVP, CDR USPHS

National Infectious Disease Clinical Pharmacist
Immigration and Customs Enforcement Health Service Corps
Littleton, MA

Disclosure: Author has nothing to disclose

Maria Lopez, PharmD

President
Mission Wellness
San Francisco, CA

Disclosure: Owner, Mission Wellness Pharmacy

Christina M. Madison, PharmD, FCCP, AAHIVP

Founder and CEO
The Public Health Pharmacist, PLLC.
Las Vegas, NV

Disclosure: Speaker Bureau, Janssen Therapeutics; Advisory Board, Pfizer (Oral COVID-19 antivirals)

Crystal Madrigal, PharmD, MBA, BCPS, CDCES, AAHIVP, CDR USPHS

Supervisory Lead Pharmacist
Immigration and Customs Enforcement Health Service Corps
Batavia, NY

Disclosure: Author has nothing to disclose

Alex R. Mills, PharmD, BCACP, AAHIVP

Ambulatory Cardiology Clinical Pharmacist
Community Health Network
Indianapolis, IN

Disclosure: Author has nothing to disclose

Zachary Oleszczuk, PharmD, MSPharm, BCGP

Commander
United States Public Health Service
Lutherville, MD

Disclosure: Author has nothing to disclose

Tam Phan, PharmD, AAHIVP

Assistant Professor of Clinical Pharmacy
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Los Angeles, CA

Disclosure: Author has nothing to disclose

Tami Rodriguez, PharmD, MS, BCPS, AAHIVP, CAPT USPHS

Director of Pharmacy Programs
Federal Bureau of Prisons
Waterford, VA

Disclosure: Author has nothing to disclose

Dan Scales, PharmD, MHA, AAHIVP

Director of Clinical Pharmacy
Vivent Health
Denver, CO

Disclosure: Author has nothing to disclose

Haley Sedo, PharmD

Clinical Pharmacist
Vivent Health
Milwaukee, WI

Disclosure: Author has nothing to disclose

Elizabeth Sherman, PharmD

Assistant Professor of Pharmacy Practice
Nova Southeastern University
Hollywood, FL

Disclosure: Author has nothing to disclose

Drew Swigart, PharmD, BCACP, NCPS, AAHIVP, CDR USPHS

Advanced Practice Pharmacist
Federal Bureau of Prisons
Lewisburg, PA

Disclosure: Author has nothing to disclose

Elizabeth Thompson, PharmD, BCGP, AAHIVP, CDR USPHS

HIV Clinical Pharmacist Consultant Program Coordinator
Federal Bureau of Prisons
Rochester, MN

Disclosure: Author has nothing to disclose

Paul J. Weidle, PharmD, MPH, CAPT USPHS

Senior Advisor, Division of HIV Prevention
Centers for Disease Control and Prevention
Hilton Head Island, SC

Disclosure: Author has nothing to disclose

Editors

Lena Choe, PharmD, BCGP, CDR USPHS

Branch Chief, Division of Drug Information
U.S. Food and Drug Administration
Silver Spring, MD

Disclosure: Author has nothing to disclose

Neelam ‘Nelly’ Gazarian, PharmD, MS, AAHIVP, LCDR USPHS

Senior Policy Analyst
Office of Infectious Disease and HIV/AIDS Policy
Washington, D.C.

Disclosure: Author has nothing to disclose

Deborah A. Long, PharmD, BCIDP, BCPS, AAHIVP, CDR USPHS

National Infectious Disease Clinical Pharmacist
Immigration and Customs Enforcement Health Service Corps
Littleton, MA

Disclosure: Author has nothing to disclose

Zachary Oleszczuk, PharmD, MSPharm, BCGP

Commander
United States Public Health Service
Lutherville, MD

Disclosure: Author has nothing to disclose

Tami Rodriguez, PharmD, MS, BCPS, AAHIVP, CAPT USPHS

Director of Pharmacy Programs
Federal Bureau of Prisons
Waterford, VA

Disclosure: Author has nothing to disclose

Development

The Pharmacy-Based HIV Prevention Services Certificate Training Program and Implementing HIV Prevention Services Certificate Training Program Micro-credential was developed by the American Pharmacists Association. Copyright © 2024 by the American Pharmacists Association.

For complete APhA staff disclosures, please see the Education and Accreditation Information section at APhA Staff Disclosures.

Tags:

Advanced Training Education